Medicus Pharma Ltd MDCX

$1.88 -0.27 (-12.56%)

Valuation

Market cap
2,376,000
Revenue TTM
$0
Net income TTM
$-35,460,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
-10.45

Trading

Volume
86,700
Avg volume
128,056
Day's range
$1.82 – $2.18
Shares out
1,264,000
Stochastic %K
5%
Beta
0.30
Analysts
Strong Buy
Price target
$7.75

Price

Company profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly kno...

Show more

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
610 636 0184
Website
https://medicuspharma.com
Address
300 Conshohocken State Road, Suite 200, West Conshohocken, United States

Latest news